<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669523</url>
  </required_header>
  <id_info>
    <org_study_id>P_2017_007</org_study_id>
    <secondary_id>2018-001105-85</secondary_id>
    <nct_id>NCT03669523</nct_id>
  </id_info>
  <brief_title>Denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS)</brief_title>
  <acronym>DENIVOS</acronym>
  <official_title>A Multicenter Phase II Study Evaluating Denosumab (XGEVA®) in Combination With Nivolumab (OPDIVO®) as Second-line Therapy for Patients With Stage IV Non-small-Cell Lung Cancer (Squamous and Non-squamous) With Bone Metastases: DENIVOS STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Annecy Genevois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone metastases are common in Non-Small Cell Lung Cancer (NSCLC). They most often occur&#xD;
      during disease progression. It is thought that more than half of the patients with bone&#xD;
      metastases will have at least 1 skeletal-related event (SRE, i.e. pathological fractures,&#xD;
      medullary compression, analgesic radiotherapy, preventive and/or analgesic surgery and&#xD;
      hypercalcemia).&#xD;
&#xD;
      Expert and medical Society guidelines, notably European Society for Medical Oncology in 2014,&#xD;
      then in 2016, recommended using anti-resorptive agents (bisphosphonates or denosumab) to&#xD;
      prevent SREs, attenuate pain and improve the quality of life, and decrease the&#xD;
      medical-economic impact of this major metastatic site. Denosumab was accorded marketing&#xD;
      authorization in France in 2011 as an anti-resorptive agent for bone metastases to delay the&#xD;
      occurrence of SREs in lung-cancer patients.&#xD;
&#xD;
      Immunotherapy, notably immune-checkpoint inhibitors, like nivolumab (anti-programed death-1),&#xD;
      has recently become an integral part of the therapeutic arsenal against NSCLCs. Nivolumab was&#xD;
      accorded marketing authorization based on the phase III CHECKMATE 017 (squamous cell NSCLCs)&#xD;
      and CHECKMATE 057 (non-squamous cell NSCLCs) trials versus docetaxel, after the phase II&#xD;
      CHECKMATE 063 trial.&#xD;
&#xD;
      The denosumab-nivolumab combination is commonly used in current practice but has not been&#xD;
      evaluated prospectively. The aim of this trial is to evaluate the combination of denosumab&#xD;
      and nivolumab in second line of NSCLC with bone metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bone metastases are common in Non-Small Cell Lung Cancer (NSCLC), affecting 30-65% of the&#xD;
      patients, depending on the series. They most often occur during disease progression (59.7% in&#xD;
      the French Lung Cancer Group trial). The frequency of skeletal-related events (SREs)&#xD;
      (pathological fractures, medullary compression, analgesic radiotherapy, preventive and/or&#xD;
      analgesic surgery and hypercalcemia) is high. It is thought that more than half of the&#xD;
      patients with bone metastases will have at least 1 SRE, with rates ranging from 55% to 62%.&#xD;
&#xD;
      Expert and medical Society guidelines, notably European Society for Medical Oncology in 2014,&#xD;
      then in 2016, recommended using anti-resorptive agents (bisphosphonates or denosumab) to&#xD;
      prevent SREs, attenuate pain and improve the quality of life, and decrease the&#xD;
      medical-economic impact of this major metastatic site.&#xD;
&#xD;
      Denosumab is a humanized monoclonal antibody. It mimics the action of osteoprotegerin (OPG),&#xD;
      thereby inhibiting osteoclastogenesis by blocking the binding of the receptor activator of&#xD;
      nuclear factor-kappaB (RANK) to its ligand (RANKL), and thus interrupts the vicious circle&#xD;
      between tumor cells and bone. RANK is a transmembrane protein expressed on osteoclasts, and&#xD;
      its ligand, RANKL, is soluble and secreted by osteoblasts. Denosumab was accorded marketing&#xD;
      authorization in France in 2011 as an anti-resorptive agent for bone metastases to delay the&#xD;
      occurrence of SREs in lung-cancer patients. The results of 3 phase III studies evaluating the&#xD;
      place of denosumab versus zoledronic acid have been published. Lung cancers were included in&#xD;
      the trial examining solid tumors (other than breast and prostate) and multiple myeloma, and&#xD;
      represented 40% of the population. In a non-inferiority analysis, the primary objective was&#xD;
      reached with denosumab prolonging by approximately 4 months the time to the first SRE (20.6&#xD;
      versus 16.3 months, hazard ratio 0.84 [95% confidence interval 0.71-0.98] p=0.0007). In the&#xD;
      lung-cancer subgroup, this difference did not reach significance (hazard ratio 0.85 [95%&#xD;
      confidence interval 0.65-1.12]). In contrast, the exploratory analysis of that subgroup&#xD;
      showed overall survival prolonged by 1.2 months for the denosumab arm versus zoledronic acid&#xD;
      (8.9 versus 7.7 months, hazard ratio 0.8 [95% confidence interval 0.67-0.95] p=0.01).&#xD;
&#xD;
      Immunotherapy, notably immune-checkpoint inhibitors (ICPIs), like nivolumab (anti-programed&#xD;
      death-1 (PD-1)), has recently become an integral part of the therapeutic arsenal against&#xD;
      NSCLCs. Nivolumab was accorded marketing authorization based on the phase III CHECKMATE 017&#xD;
      (squamous cell NSCLCs) and CHECKMATE 057 (non-squamous cell NSCLCs) trials versus docetaxel,&#xD;
      after the phase II CHECKMATE 063 trial. The search for a biomarker predictive of the response&#xD;
      to immunotherapy is becoming more-and-more crucial, so as not to expose patients who risk&#xD;
      early cancer hyper-progression. Immunohistochemical labeling of PD-1 ligand (PD-L1) on tumor&#xD;
      cells (± infiltrating the stroma) is the most studied and reliable biomarker. Knowing its&#xD;
      status has become indispensable in immunotherapy trials because an elevated PD-L1 has been&#xD;
      correlated to a better response. Prescribing second-line nivolumab is not conditioned by the&#xD;
      PD-L1 status because those trials had not foreseen stratification according to this&#xD;
      criterion's status. However, post-hoc analysis of PD-L1 in the CHECKMATE 057 trial on&#xD;
      non-squamous cell NSCLCs showed prolonged overall survival for patients with PD-L1-positive&#xD;
      tumors, whether the positivity threshold was 1%, 5% or 10%. Thus, knowing the PD-L1 status is&#xD;
      necessary to interpret the results of immunotherapy trials.&#xD;
&#xD;
      The RANK-RANKL system was studied in preclinical osteoimmunology models. It is expressed by&#xD;
      certain cells, notably antigen-presenting cells, such as dendritic cells or lymphocytes,&#xD;
      essential for the adaptive immunity function solicited by immunotherapy. It is part of the&#xD;
      tumor necrosis factor receptor (TNF-R) family and is implicated in the interactions between&#xD;
      dendritic cells and lymphocytes. The RANK-RANKL role in the development and function of&#xD;
      regulatory T cells (Tregs) remains poorly elucidated. Information on the interaction of the&#xD;
      RANK-RANKL system and adaptive immunity obtained with the preclinical models is discordant&#xD;
      and rare. A case report on a patient with melanoma bone metastases treated with denosumab and&#xD;
      ipilimumab (ICPI of the anti-cytotoxic T-lymphocyte antigen 4 type) obtained a promising&#xD;
      carcinological outcome, without any sign of deleterious interaction.&#xD;
&#xD;
      The aim of this trial is to evaluate the combination of denosumab and nivolumab in second&#xD;
      line of NSCLC with bone metastases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>National (French), multicenter, prospective, open, single-arm phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) according to the PD-L1-expression rate (threshold set at 1%)</measure>
    <time_frame>At 24 months</time_frame>
    <description>ORR (Complete and Partial Responses) will be expressed as number, percentage and 95% confidence interval, calculated with the exact method.&#xD;
The evaluation of ORR, according to PD-L1-expression rate, using RECIST criteria 1.1, will be performed by the investigator in each center. A panel of French Lung Cancer Group investigators meeting 3 times/year will then validate it by a second reading.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-control rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The DCR (complete and partial responses + stabilized disease using RECIST criteria 1.1) will be expressed as number, percentage and 95% confidence interval, calculated with the exact method, for the entire population, then by subgroups according to the PD-L1-expression rate, and histological type (adenocarcinoma versus squamous-cell).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>over 24 months</time_frame>
    <description>Overall survival over 24 months will be described using the Kaplan-Meier method. Log-rank tests will be used to analyze subgroups according to PD-L1-expression rate, then histological type (adenocarcinoma versus squamous-cell). Survival medians, in the overall population and according to PD-L1-expression rate, then histological type (adenocarcinoma versus squamous-cell) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>over 24 months</time_frame>
    <description>Progression-free survival over 24 months will be described with the Kaplan-Meier method. Log-rank tests will be used to analyze subgroups according to PD-L1-expression rate, then histological type (adenocarcinoma versus squamous-cell). Progression-free survival medians, in the overall population and according to PD-L1-expression rate, then histological type (adenocarcinoma versus squamous-cell) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate for the entire population</measure>
    <time_frame>At 24 months</time_frame>
    <description>The 24-month Overall Response Rate (Complete and Partial Responses using RECIST criteria 1.1) for the entire population, then according to histological type (adenocarcinoma versus squamous-cell) will be expressed as number, percentage and 95% confidence interval, calculated with the exact method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate according to the histological type (adenocarcinoma versus squamous cell)</measure>
    <time_frame>At 24 months</time_frame>
    <description>The 24-month Overall Response Rate (Complete and Partial Responses using RECIST criteria 1.1) for the entire population, then according to histological type (adenocarcinoma versus squamous-cell) will be expressed as number, percentage and 95% confidence interval, calculated with the exact method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first Skeletal-Related Event in months</measure>
    <time_frame>Over 24 months</time_frame>
    <description>The time to an Skeletal-Related Event will be estimated with the Kaplan-Meier method over 24 months of follow-up.&#xD;
Skeletal-Related Event are defined as pathological fractures, medullary compression, analgesic radiotherapy, preventive and/or analgesic surgery and hypercalcemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, serious adverse events, deaths and biological abnormalities</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Scored according to NCI CTCAE V4.0 terminology</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Denosumab-nivolumab combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both drugs to be continued until progression or unacceptable toxicity and for a maximum of two years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab-nivolumab combination</intervention_name>
    <description>Denosumab: 120 mg every 4 weeks subcutaneously&#xD;
Nivolumab: 240mg intravenously on day 1 every 2 weeks</description>
    <arm_group_label>Denosumab-nivolumab combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytologically or histologically proven stage IV NSCLC&#xD;
&#xD;
          -  Patients who had received first-line platin salt-based chemotherapy and will be given&#xD;
             second-line nivolumab;&#xD;
&#xD;
          -  Patients with bone metastases, symptomatic or not, confirmed by X-rays, CT scan, MRI,&#xD;
             PET-CT scan or technetium bone scintigraphy&#xD;
&#xD;
          -  Presence of at least 1 measurable target lesion, according to RECIST criteria 1.1, in&#xD;
             a non-irradiated site&#xD;
&#xD;
          -  For non-squamous cell NSCLC, patients without known activating epidermal growth factor&#xD;
             receptor mutation, anaplastic lymphoma kinase (ALK) or reactive oxygen species (ROS)-1&#xD;
             translocation, or B-Raf proto-oncogene, serine/threonine kinase (BRAF V600) mutation&#xD;
&#xD;
          -  PD-L1 status known and expressed as a percentage of tumor cells; assessed at the&#xD;
             diagnosis or the more recent PD-L1 expression status available.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status 0/1&#xD;
&#xD;
          -  Estimated life-expectancy ≥12 weeks&#xD;
&#xD;
          -  No prior malignant tumor during the previous 5 years, except for in situ carcinomas of&#xD;
             the cervix or basal or squamous cell carcinomas of the skin adequately treated;&#xD;
&#xD;
          -  Adequate organ function determined by laboratory analyses less than 7 days before&#xD;
             inclusion:&#xD;
&#xD;
               -  Normal hepatic function: bilirubin &lt; 1.5× normal (N), alanine aminotransferase&#xD;
                  and aspartate aminotransferase &lt;2.5× N or &lt;5× N if hepatic metastases are present&#xD;
&#xD;
               -  Renal function (renal clearance of creatinine at least ≥45 mL/min)&#xD;
&#xD;
               -  Hematological function: absolute number of neutrophils ≥1.5×109/L and/or&#xD;
                  platelets ≥100×109/L, hemoglobin ≥8 g/dL&#xD;
&#xD;
          -  Women of child-bearing age must use an effective contraceptive method and mechanical&#xD;
             contraception during and up to 6 months after the end of treatment;&#xD;
&#xD;
          -  Men must use effective contraception during and up to 6 months after the treatment&#xD;
             period&#xD;
&#xD;
          -  Patient with asymptomatic brain metastases (treated or not) OR symptomatic brain&#xD;
             metastases but adequately treated and controlled at the time of enrolment (without or&#xD;
             with corticotherapy ≤ 10mg/day), can be included. Carcinomatous meningitis is excluded&#xD;
             regardless of clinical stability&#xD;
&#xD;
          -  Subjects must have signed and dated an approved written informed consent form in&#xD;
             accordance with regulatory and institutional guidelines. This must be obtained before&#xD;
             the performance of any protocol related procedures that are not part of normal subject&#xD;
             care&#xD;
&#xD;
          -  Patient affiliated or benefitting from the French national health insurance program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients previously treated with immunotherapy&#xD;
&#xD;
          -  Patients with symptomatic cerebral metastases not treated and not controlled&#xD;
&#xD;
          -  Contraindication to nivolumab use:&#xD;
&#xD;
               -  Prior autoimmune disease(s), define as disease required systemic treatment in the&#xD;
                  past (i.e. with use of disease modifying agents, corticosteroids or&#xD;
                  immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or&#xD;
                  physiologic corticosteroid replacement therapy for adrenal or pituitary&#xD;
                  insufficiency, etc.) is not considered a form of systemic treatment&#xD;
&#xD;
               -  Prior diffuse interstitial pneumopathy&#xD;
&#xD;
               -  Systemic immunosuppressive therapy; define as steroid medication at a dose&#xD;
                  greater than prednisone 10 mg/day or equivalent. For patients with mismatch&#xD;
                  repair-deficient high-grade gliomas, concurrent steroid medication at a dose&#xD;
                  greater than prednisone 20mg/day or equivalent&#xD;
&#xD;
          -  Contraindication for denosumab use:&#xD;
&#xD;
               -  Poor dental status requiring immediate specialized management, like oral surgery&#xD;
&#xD;
               -  Prior or current signs of osteonecrosis of the jaw/osteomyelitis&#xD;
&#xD;
               -  Invasive dental intervention schedule during the study or not yet healed&#xD;
&#xD;
          -  Patient with known sensitivity to any of the products to be administered during the&#xD;
             study&#xD;
&#xD;
          -  Concomitant administration of bisphosphonates&#xD;
&#xD;
          -  Hypocalcemia or severe uncorrected hypercalcemia&#xD;
&#xD;
          -  Medical or psychological condition preventing informed consent&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  PD-L1-status results unavailable&#xD;
&#xD;
          -  Simultaneous participation of the patient in another clinical research trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal Decroisette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Annecy Genevois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion GHIDI</last_name>
    <phone>+33450537031</phone>
    <email>mghidi@ch-annnecygenevois.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale Cony-Makhoul</last_name>
    <phone>+33450636431</phone>
    <email>pconymakhoul@ch-annecygenevois.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie BERNARDI, MD</last_name>
      <phone>+33442335067</phone>
      <email>mbernardi@ch-aix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry URBAN, MD</last_name>
      <phone>+33241355844</phone>
      <email>thurban@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacky CREQUIT, MD</last_name>
      <phone>+33344112223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Fleyriat</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Morvan - Institut de Cancérologie et d'Hématologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles QUERE, MD</last_name>
      <phone>+33298223428</phone>
      <email>gilles.quere@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MONNET, MD</last_name>
      <phone>+33145175017</phone>
      <email>Isabelle.Monnet@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Intercommunal Elbeuf Louvier Val de Reuil</name>
      <address>
        <city>Elbeuf</city>
        <zip>76503</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal des Alpes du Sud</name>
      <address>
        <city>Gap</city>
        <zip>05000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33505</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Marne La Vallée</name>
      <address>
        <city>Marne-La-Vallée</city>
        <zip>77600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine LEFOLL, MD</last_name>
      <phone>+331 61 10 61 37</phone>
      <email>j.letreut@hopital-europeen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Européen</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT, MD</last_name>
      <phone>+33413427237</phone>
      <email>j.letreut@hopital-europeen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Nord APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GREILLIER, MD</last_name>
      <phone>+33491965901</phone>
      <email>laurent.greillier@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Oncologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine VIEILLOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Annecy-Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal DECROISETTE, MD</last_name>
      <phone>+33450636603</phone>
      <email>cdecroisette@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Pontchailloux</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé LENA, MD</last_name>
      <phone>+33299282481</phone>
      <email>herve.lena@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian GUISIER, MD</last_name>
      <phone>+332 32 88 80 79</phone>
      <email>florian.guisier@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion - Site de Bellepierre</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97411</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel ANDRE, MD</last_name>
      <email>michel.andre@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud Réunion - CHU de la Réunion</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FOURNEL, MD</last_name>
      <phone>+33477917036</phone>
      <email>pierre.fournel@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLCC Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland SCHOTT, MD</last_name>
      <phone>+33388252456</phone>
      <email>rschott@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bigorre</name>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axelle DEMAEGDT, MD</last_name>
      <phone>+33562546277</phone>
      <email>ademaegdt@ch-tarbes-vic.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Saint-Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83041</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri BERARD, MD</last_name>
      <phone>+33483162503</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHITS Toulon Sainte-Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot Centre Hospitalier de Versailles</name>
      <address>
        <city>Versailles</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Villefranche sur Saone</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel FALCHERO, MD</last_name>
      <phone>+33474092723</phone>
      <email>lfalchero@ch-villefranche.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

